ArticleInfectious diseases and therapy2024

Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor.

Takayuki Katsube et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.